Literature DB >> 19789351

Oncogenesis caused by loss of the SNF5 tumor suppressor is dependent on activity of BRG1, the ATPase of the SWI/SNF chromatin remodeling complex.

Xi Wang1, Courtney G Sansam, Christopher S Thom, Daniel Metzger, Julia A Evans, Phuong T L Nguyen, Charles W M Roberts.   

Abstract

Alterations in chromatin play an important role in oncogenic transformation, although the underlying mechanisms are often poorly understood. The SWI/SNF complex contributes to epigenetic regulation by using the energy of ATP hydrolysis to remodel chromatin and thus regulate transcription of target genes. SNF5, a core subunit of the SWI/SNF complex, is a potent tumor suppressor that is specifically inactivated in several types of human cancer. However, the mechanism by which SNF5 mutation leads to cancer and the role of SNF5 within the SWI/SNF complex remain largely unknown. It has been hypothesized that oncogenesis in the absence of SNF5 occurs due to a loss of function of the SWI/SNF complex. Here, we show, however, distinct effects for inactivation of Snf5 and the ATPase subunit Brg1 in primary cells. Further, using both human cell lines and mouse models, we show that cancer formation in the absence of SNF5 does not result from SWI/SNF inactivation but rather that oncogenesis is dependent on continued presence of BRG1. Collectively, our results show that cancer formation in the absence of SNF5 is dependent on the activity of the residual BRG1-containing SWI/SNF complex. These findings suggest that, much like the concept of oncogene addiction, targeted inhibition of SWI/SNF ATPase activity may be an effective therapeutic approach for aggressive SNF5-deficient human tumors.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19789351      PMCID: PMC2763035          DOI: 10.1158/0008-5472.CAN-09-0733

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  50 in total

1.  Germ-line and acquired mutations of INI1 in atypical teratoid and rhabdoid tumors.

Authors:  J A Biegel; J Y Zhou; L B Rorke; C Stenstrom; L M Wainwright; B Fogelgren
Journal:  Cancer Res       Date:  1999-01-01       Impact factor: 12.701

Review 2.  Alteration of nucleosome structure as a mechanism of transcriptional regulation.

Authors:  J L Workman; R E Kingston
Journal:  Annu Rev Biochem       Date:  1998       Impact factor: 23.643

3.  The SWI/SNF complex creates loop domains in DNA and polynucleosome arrays and can disrupt DNA-histone contacts within these domains.

Authors:  D P Bazett-Jones; J Côté; C C Landel; C L Peterson; J L Workman
Journal:  Mol Cell Biol       Date:  1999-02       Impact factor: 4.272

4.  Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a.

Authors:  M Serrano; A W Lin; M E McCurrach; D Beach; S W Lowe
Journal:  Cell       Date:  1997-03-07       Impact factor: 41.582

5.  Baf60c is essential for function of BAF chromatin remodelling complexes in heart development.

Authors:  Heiko Lickert; Jun K Takeuchi; Ingo Von Both; Johnathon R Walls; Fionnuala McAuliffe; S Lee Adamson; R Mark Henkelman; Jeffrey L Wrana; Janet Rossant; Benoit G Bruneau
Journal:  Nature       Date:  2004-11-04       Impact factor: 49.962

6.  Structure-function analysis of integrase interactor 1/hSNF5L1 reveals differential properties of two repeat motifs present in the highly conserved region.

Authors:  A Morozov; E Yung; G V Kalpana
Journal:  Proc Natl Acad Sci U S A       Date:  1998-02-03       Impact factor: 11.205

7.  Reconstitution of a core chromatin remodeling complex from SWI/SNF subunits.

Authors:  M L Phelan; S Sif; G J Narlikar; R E Kingston
Journal:  Mol Cell       Date:  1999-02       Impact factor: 17.970

8.  Altered control of cellular proliferation in the absence of mammalian brahma (SNF2alpha).

Authors:  J C Reyes; J Barra; C Muchardt; A Camus; C Babinet; M Yaniv
Journal:  EMBO J       Date:  1998-12-01       Impact factor: 11.598

9.  Truncating mutations of hSNF5/INI1 in aggressive paediatric cancer.

Authors:  I Versteege; N Sévenet; J Lange; M F Rousseau-Merck; P Ambros; R Handgretinger; A Aurias; O Delattre
Journal:  Nature       Date:  1998-07-09       Impact factor: 49.962

10.  Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization.

Authors:  F Zindy; C M Eischen; D H Randle; T Kamijo; J L Cleveland; C J Sherr; M F Roussel
Journal:  Genes Dev       Date:  1998-08-01       Impact factor: 11.361

View more
  79 in total

1.  BRG1 expression is increased in human glioma and controls glioma cell proliferation, migration and invasion in vitro.

Authors:  Jin Bai; Peng-Jin Mei; Hui Liu; Chen Li; Wang Li; Yong-Ping Wu; Zheng-Quan Yu; Jun-Nian Zheng
Journal:  J Cancer Res Clin Oncol       Date:  2012-02-24       Impact factor: 4.553

2.  Loss of the tumor suppressor Snf5 leads to aberrant activation of the Hedgehog-Gli pathway.

Authors:  Zainab Jagani; E Lorena Mora-Blanco; Courtney G Sansam; Elizabeth S McKenna; Boris Wilson; Dongshu Chen; Justin Klekota; Pablo Tamayo; Phuong T L Nguyen; Michael Tolstorukov; Peter J Park; Yoon-Jae Cho; Kathy Hsiao; Silvia Buonamici; Scott L Pomeroy; Jill P Mesirov; Heinz Ruffner; Tewis Bouwmeester; Sarah J Luchansky; Joshua Murtie; Joseph F Kelleher; Markus Warmuth; William R Sellers; Charles W M Roberts; Marion Dorsch
Journal:  Nat Med       Date:  2010-11-14       Impact factor: 53.440

3.  Swi/Snf chromatin remodeling/tumor suppressor complex establishes nucleosome occupancy at target promoters.

Authors:  Michael Y Tolstorukov; Courtney G Sansam; Ping Lu; Edward C Koellhoffer; Katherine C Helming; Burak H Alver; Erik J Tillman; Julia A Evans; Boris G Wilson; Peter J Park; Charles W M Roberts
Journal:  Proc Natl Acad Sci U S A       Date:  2013-05-30       Impact factor: 11.205

4.  PRC2-mediated repression of SMARCA2 predicts EZH2 inhibitor activity in SWI/SNF mutant tumors.

Authors:  Thomas Januario; Xiaofen Ye; Russell Bainer; Bruno Alicke; Tunde Smith; Benjamin Haley; Zora Modrusan; Stephen Gould; Robert L Yauch
Journal:  Proc Natl Acad Sci U S A       Date:  2017-10-30       Impact factor: 11.205

5.  Functional epigenetics approach identifies BRM/SMARCA2 as a critical synthetic lethal target in BRG1-deficient cancers.

Authors:  Gregory R Hoffman; Rami Rahal; Frank Buxton; Kay Xiang; Gregory McAllister; Elizabeth Frias; Linda Bagdasarian; Janina Huber; Alicia Lindeman; Dongshu Chen; Rodrigo Romero; Nadire Ramadan; Tanushree Phadke; Kristy Haas; Mariela Jaskelioff; Boris G Wilson; Matthew J Meyer; Veronica Saenz-Vash; Huili Zhai; Vic E Myer; Jeffery A Porter; Nicholas Keen; Margaret E McLaughlin; Craig Mickanin; Charles W M Roberts; Frank Stegmeier; Zainab Jagani
Journal:  Proc Natl Acad Sci U S A       Date:  2014-02-11       Impact factor: 11.205

6.  CARMA: CARM1 methylation of SWI/SNF in breast cancer.

Authors:  Xiaofeng Wang; Charles W M Roberts
Journal:  Cancer Cell       Date:  2014-01-13       Impact factor: 31.743

7.  Aberrant BAF57 signaling facilitates prometastatic phenotypes.

Authors:  Sucharitha Balasubramaniam; Clay E S Comstock; Adam Ertel; Kwang Won Jeong; Michael R Stallcup; Sankar Addya; Peter A McCue; William F Ostrander; Michael A Augello; Karen E Knudsen
Journal:  Clin Cancer Res       Date:  2013-03-14       Impact factor: 12.531

Review 8.  A rationale to target the SWI/SNF complex for cancer therapy.

Authors:  Anja F Hohmann; Christopher R Vakoc
Journal:  Trends Genet       Date:  2014-06-03       Impact factor: 11.639

9.  Combined gene dosage requirement for SWI/SNF catalytic subunits during early mammalian development.

Authors:  Stephanie L Smith-Roe; Scott J Bultman
Journal:  Mamm Genome       Date:  2012-10-18       Impact factor: 2.957

10.  Glioma tumor suppressor candidate region gene 1 (GLTSCR1) and its paralog GLTSCR1-like form SWI/SNF chromatin remodeling subcomplexes.

Authors:  Aktan Alpsoy; Emily C Dykhuizen
Journal:  J Biol Chem       Date:  2018-01-26       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.